hVIVO (LON:HVO) Stock Price Crosses Below 50-Day Moving Average – What’s Next?

Shares of hVIVO plc (LON:HVO) crossed below its fifty day moving average during trading on Friday . The stock has a fifty day moving average of GBX 6.09 and traded as low as GBX 6. hVIVO shares last traded at GBX 6.19, with a volume of 4,538,179 shares.

Wall Street Analyst Weigh In

A number of analysts have weighed in on HVO shares. Peel Hunt reiterated an “add” rating and issued a GBX 10 target price on shares of hVIVO in a research note on Thursday, November 20th. Shore Capital reduced their price target on shares of hVIVO from GBX 35 to GBX 25 and set a “buy” rating on the stock in a research note on Tuesday, September 23rd. Two equities research analysts have rated the stock with a Buy rating, Based on data from MarketBeat, the stock has an average rating of “Buy” and a consensus target price of GBX 17.50.

hVIVO Stock Up 2.1%

The company has a debt-to-equity ratio of 33.86, a quick ratio of 1.16 and a current ratio of 1.61. The company has a fifty day simple moving average of GBX 6.09 and a two-hundred day simple moving average of GBX 8.16. The firm has a market capitalization of £42.50 million, a PE ratio of 8.03 and a beta of 0.97.

Insider Transactions at hVIVO

In other hVIVO news, insider Stephen Pinkerton bought 520,000 shares of the business’s stock in a transaction on Monday, December 15th. The shares were acquired at an average price of GBX 6 per share, with a total value of £31,200. Also, insider Yamin Mo’ Khan purchased 3,310,405 shares of the stock in a transaction dated Monday, December 15th. The stock was acquired at an average cost of GBX 6 per share, with a total value of £198,624.30. Company insiders own 4.43% of the company’s stock.

About hVIVO

hVIVO plc operates as a pharmaceutical service and contract research company. The company is involved in testing vaccines and antivirals using human challenge clinical trials. It provides services to big pharma, biotech, government, and public health organizations. The company has a portfolio of human challenge study models for conditions, such as RSV, flu, human rhinovirus, asthma, malaria, cough, and COPD, as well as developing COVID-19 human challenge study model. In addition, the company is developing a database of infectious disease progression data that include Disease in Motion platform, which comprises unique datasets, such as clinical, immunological, virological, and digital (wearable) biomarkers.